Avalo Therapeutics Appoints Michael Heffernan as Chairman

Story Highlights
Avalo Therapeutics Appoints Michael Heffernan as Chairman

An update from Avalo Therapeutics ( (AVTX) ) is now available.

On March 25, 2025, Avalo Therapeutics appointed Michael Heffernan as Chairman of the Board, succeeding Dr. Garry Neil, who will remain as CEO and a Board member. This strategic move aims to leverage Heffernan’s extensive experience in biopharmaceuticals to advance Avalo’s pipeline, particularly the Phase 2 LOTUS trial for hidradenitis suppurativa, and aligns with the company’s growth and strategic direction.

More about Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on treating immune dysregulation. Its lead asset, AVTX-009, is an anti-IL-1β monoclonal antibody targeting inflammatory diseases.

YTD Price Performance: 1.30%

Average Trading Volume: 78,576

Technical Sentiment Signal: Buy

Current Market Cap: $91.14M

For detailed information about AVTX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App